COCP - Cocrystal Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7203
+0.0253 (+3.64%)
At close: 4:00PM EDT

0.7400 +0.02 (2.73%)
After hours: 6:16PM EDT

Stock chart is not supported by your current browser
Previous Close0.6950
Open0.6800
Bid0.7202 x 800
Ask0.7350 x 27000
Day's Range0.6500 - 0.7400
52 Week Range0.3900 - 2.9500
Volume1,504,501
Avg. Volume5,545,377
Market Cap37.557M
Beta (5Y Monthly)-1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.5120
Earnings DateMar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • GlobeNewswire

    Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

    Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration.

  • GlobeNewswire

    Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market

    The gross proceeds to the Company from the offering totaled approximately $6.8 million, before deducting placement agent fees and offering expenses. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus supplement and the accompanying prospectus relating to the shares of common stock were filed by Cocrystal with the SEC and can be obtained at the SEC’s website at www.sec.gov.

  • Company News for Mar 10, 2020
    Zacks

    Company News for Mar 10, 2020

    Companies In The News Are: COCP, CGEN, AAPL, NINE

  • GlobeNewswire

    Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market

    H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

  • GlobeNewswire

    Cocrystal Pharma Announces Plans to Advance Coronavirus Program

    Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial.

  • GlobeNewswire

    Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

    COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 8,461,540 shares of its common stock at a purchase price of $1.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $11.0 million, before deducting placement agent fees and offering expenses. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and Exchange Commission (“SEC”).

  • GlobeNewswire

    Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market

    COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,461,540 shares of its common stock at a price of $1.30 per share, for aggregate gross proceeds of approximately $11.0 million, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the Securities and Exchange Commission (SEC).

  • Benzinga

    18 Medical Stocks To Watch Amid The Coronavirus Outbreak

    Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.

  • GlobeNewswire

    Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds

    BOTHELL, WA, Feb. 24, 2020 -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used.

  • Those Who Purchased Cocrystal Pharma (NASDAQ:COCP) Shares Five Years Ago Have A 98% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Cocrystal Pharma (NASDAQ:COCP) Shares Five Years Ago Have A 98% Loss To Show For It

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

  • GlobeNewswire

    Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals

    –   Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address.

  • GlobeNewswire

    Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

    – Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical.

  • GlobeNewswire

    COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING

    BOTHELL, WA, Feb. 03, 2020 -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel.

  • GlobeNewswire

    COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING

    The Company intends to use the net proceeds for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the SEC.

  • Bothell-based biotech at risk of losing Nasdaq standing
    American City Business Journals

    Bothell-based biotech at risk of losing Nasdaq standing

    Cocrystal has nearly $73.5 million in total assets, including nearly $6 million in cash, but that may be enough to keep the company in business.

  • GlobeNewswire

    Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

    – Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical.

  • GlobeNewswire

    Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C.

  • GlobeNewswire

    Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

    BOTHELL, WA, Nov. 11, 2019 (GLOBE NEWSWIRE) --  Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, presented at the AASLD 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA, new data in a poster demonstrating positive data from its triple regimen, U.S. Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultrashort treatment of HCV infected individuals. The poster titled, “Immune Cell Phenotypes Associated with Successful Response to 2 Weeks of a Novel Non-Nucleoside Inhibitor CDI-31244 Concurrent with 6 Weeks of Sofosbuvir/Velpatasvir in Subjects with Chronic Hepatitis C Genotype 1 Infection,” was presented by Joel Chua, MD, Assistant Professor of Medicine of the Institute of Human Virology at the University of Maryland School of Medicine and Principal Investigator of the U.S. Phase 2a trial, on Sunday November 10, 2019 and is available on the Company’s website here.

  • GlobeNewswire

    COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING

    COCRYSTAL PHARMA, INC. (COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.0 million before deducting underwriting discounts and expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes. The Company also granted the underwriters a 45-day option to purchase up to 529,411 additional shares of common stock to cover over-allotments, if any, at the public offering price.

  • GlobeNewswire

    COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

    COCRYSTAL PHARMA, INC. (COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriters a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for operations, including payment of general and administrative expenses and other working capital and general corporate purposes.

  • GlobeNewswire

    Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that its poster demonstrating positive data from its triple regimen, U.S. Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultra-short treatment of HCV infected individuals was selected for presentation at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA. “We are pleased to be presenting this positive data at the AASLD 2019 meeting.

  • Is Cocrystal Pharma, Inc. (NASDAQ:COCP) Overpaying Its CEO?
    Simply Wall St.

    Is Cocrystal Pharma, Inc. (NASDAQ:COCP) Overpaying Its CEO?

    In 2016 Gary Wilcox was appointed CEO of Cocrystal Pharma, Inc. (NASDAQ:COCP). This report will, first, examine the...

  • GlobeNewswire

    Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, presented positive data from its unique structure-based drug design platform technology at the 26th International Symposium on Hepatitis C Virus and Related Viruses (“HCV2019”) Conference being held on October 5-8, 2019 in Seoul, South Korea. As part of his poster presentation, Dr. Lee provided an overview of the Company's proprietary structure-based drug discovery technology which has demonstrated the ability to design and develop a high barrier to drug resistance and to be a highly potent, selective non-nucleoside inhibitor (NNI) that is active against all HCV genotypes (1-6) with low level cytotoxicity in multiple cell types.

  • GlobeNewswire

    Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, will present data from its unique structure-based drug design platform technology at the 26th International Symposium on Hepatitis C Virus and Related Viruses (“HCV2019”) Conference being held October 5-8, 2019 in Seoul, South Korea. The Company's proprietary structure-based drug discovery technology has demonstrated the ability to design and develop a high barrier to drug resistance and to be a highly potent, selective NNI that is active against all HCV genotypes (1-6) with low level cytotoxicity in multiple cell types.

  • GlobeNewswire

    Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that James Martin, Chief Financial Officer of Cocrystal will present a corporate overview at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 1:45 PM ET in New York, NY. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.